Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0000501

Trandolapril

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H34N2O5
CAS Number:
87679-37-6
Molecular Weight:
430.54
MDL number:
MFCD00865776
UNSPSC Code:
41116107
PubChem Substance ID:
329830986
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

trandolapril

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O

InChI

1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

InChI key

VXFJYXUZANRPDJ-WTNASJBWSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Trandolapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360D

Hazard Classifications

Repr. 1B

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Buksa
Medicinski arhiv, 54(2), 103-106 (2000-08-10)
Left ventricle systolic dysfunction and congestive heart failure after AMI are still a great problem in cardiology. Introduction of angiotensin converting enzyme (ACE) inhibitors after AMI has been a new step in therapy of the left ventricle systolic disfunction. Some
C A Gaillard et al.
American heart journal, 125(5 Pt 2), 1542-1546 (1993-05-01)
In this article the clinical experiences with the new non-sulfhydryl angiotensin-converting enzyme inhibitor trandolapril are reviewed. The drug lowers blood pressure effectively in patients with mild-to-severe hypertension including elderly and obese patients. Distinguishing features of the compound are its long
Ariel Diaz et al.
Vascular health and risk management, 4(6), 1147-1158 (2008-01-01)
Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine.
H Holzgreve
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 15(2), S51-S53 (1997-03-01)
ADVANTAGES OF DRUG COMBINATIONS: The particular advantage usually sought with antihypertensive drug combinations is an improvement in blood pressure control. However, at least as important is a consideration of adverse reactions and the safety of the combination compared to monotherapy.
Sanjib Kumar Sharma et al.
Vascular health and risk management, 3(4), 453-465 (2007-11-01)
Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service